Symbiosis Pharmaceutical Services Appoints Joanne Anderson as Chief Commercial Officer
Symbiosis Pharmaceutical Services has appointed Joanne Anderson as CCO, tasking her with leading global commercial strategy as the CDMO expands capacity and strengthens presence across North America and Europe.
CDMO | 13/03/2026 | By News Bureau
Piramal Pharma Solutions Commercialises Tablet-in-Capsule Technology at Indian Manufacturing Sites
Piramal Pharma Solutions has successfully developed and commercialised a tablet-in-capsule drug delivery system in India, enabling flexible dosing, dual-release profiles and improved patient-centric oral therapies.
CDMO | 03/02/2026 | By News Bureau | 150
Agno Pharma Acquires Actylis's CDMO Manufacturing Asset
Agno Pharma has acquired Actylis’s CDMO manufacturing asset, the legacy Cascade Chemistry business based in Eugene, Oregon, strengthening Agno’s U. cGMP API development and manufacturing capabilities.
CDMO | 19/01/2026 | By News Bureau | 145
Rakuten Medical and LOTTE Biologics Sign Manufacturing Deal for Global Oncology Programme
Rakuten Medical has entered into a manufacturing agreement with LOTTE Biologics under which LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates, supporting Rakuten Medical’s global clinical development programmes and future commercialisation in oncology.
CDMO | 19/01/2026 | By News Bureau | 128
Under the agreement, Transcenta will grant EirGenix a non-exclusive licence to use its Highly Intensified Continuous Bioprocessing (HiCB) platform, including highly productive continuous perfusion and integrated hybrid continuous purification process technologies, along with comprehensive process documentation, know-how, and regulatory support packages.
CDMO | 30/12/2025 | By News Bureau
PharmAla Biotech Australia Ties Up with UK CDMO to Manufacture ALA-002
PharmAla Biotech Australia has contracted a UK-based CDMO to manufacture the drug substance for ALA-002, its patented non-racemic MDMA formulation, ahead of planned phase 2a/2b clinical trials for social anxiety disorder expected to begin in 2026.
CDMO | 16/12/2025 | By News Bureau | 114
Indian Pharmaceutical Alliance Welcomes New Leadership
Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, and Vice President, Indian Pharmaceutical Alliance (IPA), has been appointed President of the alliance, while Glenn Saldanha, Chairman and Managing Director, Glenmark, will serve as the new Vice President.
CDMO | 04/10/2025 | By Dineshwori | 168
Akums Becomes First Indian CDMO to Receive DCGI Approval for Innovative Glaucoma Treatment
Glaucoma ranks as the second leading cause of irreversible but preventable blindness worldwide, with India contributing to 23.5 percent of the global burden.
CDMO | 01/04/2025 | By Abha | 453
Kincell Bio Appoints New Chief Executive Officer to Drive Business Growth
Mark, who has served as Chair of the Board since May 2024, brings decades of industry experience to the role and will be pivotal in advancing Kincell Bio’s mission to support innovators in the rapidly growing cell therapy sector.
CDMO | 21/01/2025 | By Aishwarya | 238
Glenmark Life Sciences Rebrands its Identity as Alivus Life Sciences
The new identity, Alivus Life Sciences, represents vitality and growth with a renewed focus.
CDMO | 20/01/2025 | By Aishwarya | 2999
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy